An academic overview of thyroid nodule evaluation, ultrasound-based risk stratification, and when to consider FNA.
Thyroid nodules are common, and most are benign. The clinical goal is to identify malignancy and clinically significant functional nodules while avoiding unnecessary procedures. Initial assessment includes history (radiation exposure, family history of thyroid cancer, compressive symptoms) and a focused examination. Serum TSH is a key first test: a low TSH suggests possible autonomy; in that setting, radionuclide scanning can identify hyperfunctioning (“hot”) nodules, which have a low likelihood of malignancy and may not require fine-needle aspiration (FNA) solely for cancer evaluation.
Ultrasound is central to risk stratification. Features such as marked hypoechogenicity, irregular margins, microcalcifications, taller-than-wide shape, and extrathyroidal extension increase suspicion, whereas spongiform appearance is often low risk. Modern practice uses structured systems (e.g., TI-RADS) to link sonographic patterns and size thresholds to FNA recommendations. Cervical lymph node assessment is part of the ultrasound evaluation, as suspicious nodes can alter management.
Cytology from FNA is reported using standardized categories, which guide follow-up: benign nodules typically undergo surveillance, while malignant or suspicious results prompt surgical consultation. Indeterminate results may be clarified by repeat FNA, molecular testing where available, or individualized clinical decision-making. Importantly, nodule size alone is not a sufficient cancer predictor; risk is better estimated by ultrasound pattern and cytology. Clear communication about expected surveillance intervals and red flags helps patients engage with longitudinal care and reduces anxiety around incidental findings.
Ultrasound is central to risk stratification. Features such as marked hypoechogenicity, irregular margins, microcalcifications, taller-than-wide shape, and extrathyroidal extension increase suspicion, whereas spongiform appearance is often low risk. Modern practice uses structured systems (e.g., TI-RADS) to link sonographic patterns and size thresholds to FNA recommendations. Cervical lymph node assessment is part of the ultrasound evaluation, as suspicious nodes can alter management.
Cytology from FNA is reported using standardized categories, which guide follow-up: benign nodules typically undergo surveillance, while malignant or suspicious results prompt surgical consultation. Indeterminate results may be clarified by repeat FNA, molecular testing where available, or individualized clinical decision-making. Importantly, nodule size alone is not a sufficient cancer predictor; risk is better estimated by ultrasound pattern and cytology. Clear communication about expected surveillance intervals and red flags helps patients engage with longitudinal care and reduces anxiety around incidental findings.
Published January 18, 2026